Application of quantitative pharmacology analysis to support early clinical development of oncology drugs: dose selection

References

• Abdolahi, S., Ghazvinian, Z., Muhammadnejad, S., Saleh, M., Asadzadeh Aghdaei, H., & Baghaei, K. (2022). Patient-derived xenograft (PDX) models, applications and challenges in cancer research. Journal of translational medicine, 20(1), 206.
   Google Scholar
• Carretero-Iglesia et al, (2024). 2024-AACR abst#1238. AACR2024_Regular_Abstracts_04-01-24.pdf
   Google Scholar
• Chen et al (2023). E14509 abstract, Journal of Clinical Oncology, page 124, Volume 41, Number 16_suppl.
   Google Scholar
• Cross, D. (2016). The journey of osimertinib discovery: from the lab to the clinic. 2016 FDA-AACR Workshop, Pages 105-126.
   Google Scholar
• Falchook, G. S., Kurzrock, R., Amin, H. M., Xiong, W., Fu, S., Piha-Paul, S. A., Janku, F., Eskandari, G., Catenacci, D. V., Klevesath, M., Bruns, R., Stammberger, U., Johne, A., Bladt, F., Friese-Hamim, M., Girard, P., El Bawab, S., & Hong, D. S. (2020). First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clinical cancer research: an official journal of the American Association for Cancer Research, 26(6), 1237–1246.
   Google Scholar
• FDA Sotorasib review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf
   Google Scholar
• Fourie Zirkelbach, J., Shah, M., Vallejo, J., Cheng, J., Ayyoub, A., Liu, J., Hudson, R., Sridhara, R., Ison, G., Amiri-Kordestani, L., Tang, S., Gwise, T., Rahman, A., Pazdur, R., & Theoret, M. R. (2022). Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 40(30), 3489–3500.
   Google Scholar
• Frances, N., Bacac, M., Bray-French, K., Christen, F., Hinton, H., Husar, E., Quackenbush, E., Schäfer, M., Schick, E., Vyver, A. V., & Richter, W. F. (2022). Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab. Journal of pharmaceutical sciences, 111(4), 1208–1218.
   Google Scholar
• Huang, W., Li, J., Liao, M. Z., Liu, S. N., Yu, J., Jing, J., Kotani, N., Kamen, L., Guelman, S., & Miles, D. R. (2022). Clinical Pharmacology Perspectives for Adoptive Cell Therapies in Oncology. Clinical pharmacology and therapeutics, 112(5), 968–981.
   Google Scholar
• Jänne, P. A., Yang, J. C., Kim, D. W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M. J., Kim, S. W., Su, W. C., Horn, L., Haggstrom, D., Felip, E., Kim, J. H., Frewer, P., Cantarini, M., Brown, K. H., Dickinson, P. A., Ghiorghiu, S., & Ranson, M. (2015). AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. The New England journal of medicine, 372(18), 1689–1699.
   Google Scholar
• Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009). Dose escalation methods in phase I cancer clinical trials. Journal of the National Cancer Institute, 101(10), 708–720.
   Google Scholar
• Muller, P. Y., Milton, M., Lloyd, P., Sims, J., & Brennan, F. R. (2009). The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Current opinion in biotechnology, 20(6), 722–729.
   Google Scholar
• Nakajima, E. C., Drezner, N., Li, X., Mishra-Kalyani, P. S., Liu, Y., Zhao, H., Bi, Y., Liu, J., Rahman, A., Wearne, E., Ojofeitimi, I., Hotaki, L. T., Spillman, D., Pazdur, R., Beaver, J. A., & Singh, H. (2022). FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC. Clinical cancer research: an official journal of the American Association for Cancer Research, 28(8), 1482–1486.
   Google Scholar
• Ribba B. (2023). Quantitative systems pharmacology in the age of artificial intelligence. CPT: pharmacometrics & systems pharmacology, 12(12), 1823–1826.
   Google Scholar
• Sheng, J., Srivastava, S., Sanghavi, K., Lu, Z., Schmidt, B. J., Bello, A., & Gupta, M. (2017). Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors. Journal of clinical pharmacology, 57 Suppl 10, S26–S42.
   Google Scholar
• Song, L., Yao, X., Liu, Y., Zhong, W., Jiang, J., Liu, H., Zhou, H., Shi, C., Zong, K., Wang, C., Ma, C., Liu, D., & Hu, P. (2020). Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods. European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences, 147, 105281.
   Google Scholar
• Sové, R. J., Jafarnejad, M., Zhao, C., Wang, H., Ma, H., & Popel, A. S. (2020). QSP-IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno-Oncology Applications. CPT: pharmacometrics & systems pharmacology, 9(9), 484–497.
   Google Scholar
• Strohbehn, G. W., & Ratain, M. J. (2024). Sotorasib dosing and incremental cost ineffectiveness - implications and lessons for stakeholders. Nature reviews. Clinical oncology, 21(5), 331–332.
   Google Scholar
• Terranova, N., Renard, D., Shahin, M. H., Menon, S., Cao, Y., Hop, C. E. C. A., Hayes, S., Madrasi, K., Stodtmann, S., Tensfeldt, T., Vaddady, P., Ellinwood, N., & Lu, J. (2024). Artificial Intelligence for Quantitative Modeling in Drug Discovery and Development: An Innovation and Quality Consortium Perspective on Use Cases and Best Practices. Clinical pharmacology and therapeutics, 115(4), 658–672.
   Google Scholar
• Upreti, V. V., & Venkatakrishnan, K. (2019). Model-Based Meta-Analysis: Optimizing Research, Development, and Utilization of Therapeutics Using the Totality of Evidence. Clinical pharmacology and therapeutics, 106(5), 981–992.
   Google Scholar
• Venkatakrishnan, K., Friberg, L. E., Ouellet, D., Mettetal, J. T., Stein, A., Trocóniz, I. F., Bruno, R., Mehrotra, N., Gobburu, J., & Mould, D. R. (2015). Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities. Clinical pharmacology and therapeutics, 97(1), 37–54.
   Google Scholar
• Vezina, H. E., Cotreau, M., Han, T. H., & Gupta, M. (2017). Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future. Journal of clinical pharmacology, 57 Suppl 10, S11–S25.
   Google Scholar
• Xiong, W., Friese-Hamim, M., Johne, A., Stroh, C., Klevesath, M., Falchook, G. S., Hong, D. S., Girard, P., & El Bawab, S. (2021). Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose. CPT: pharmacometrics & systems pharmacology, 10(5), 428–440.
   Google Scholar